| LncRNA |
Compound |
Cancer |
P-value |
Effect |
| ENSG00000250900.2 |
Avagacestat |
Bladder urothelial carcinoma |
0.028949493 |
Resistant |
| ENSG00000250900.2 |
Avagacestat |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
0.045893091 |
Resistant |
| ENSG00000250900.2 |
Avagacestat |
Sarcoma |
0.012819896 |
Sensitive |
